Septerna, Inc. (SEPN)
NASDAQ: SEPN · Real-Time Price · USD
11.99
+0.29 (2.48%)
At close: Aug 22, 2025, 4:00 PM
12.00
+0.01 (0.08%)
After-hours: Aug 22, 2025, 7:46 PM EDT
Septerna Employees
Septerna had 75 employees as of December 31, 2024.
Employees
75
Change
n/a
Growth
n/a
Revenue / Employee
$9,680
Profits / Employee
-$1,166,733
Market Cap
534.58M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SEPN News
- 2 days ago - Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases - GlobeNewsWire
- 11 days ago - Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside - Benzinga
- 3 months ago - Septerna to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist - Seeking Alpha
- 3 months ago - Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash - Seeking Alpha
- 3 months ago - Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs - Benzinga